Thrombopoietin therapeutic use

Despite abundant trials, thrombopoietin has not been begin to be advantageous therapeutically. Theoretical uses cover the accretion of platelets for donation, accretion of platelet counts afterwards myelosuppressive chemotherapy.

Trials of a adapted recombinant form, megakaryocyte advance and adverse agency (MGDF), were chock-full if advantageous volunteers developed autoantibodies to autogenous thrombopoietin and again developed thrombocytopenia. Romiplostim and Eltrombopag, structurally altered compounds that activate the aforementioned pathway, are acclimated instead.

A quadrivalent peptide alternation is getting investigated, as able-bodied as several small-molecule agents, and several non-peptide ligands of c-Mpl, which act as thrombopoietin analogues.